カテゴリ： GlobalData, 企業調査, 日本

Eisai Co Ltd (4523)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Eisai Co Ltd (4523) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9889
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：245
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：日本
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer’s agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Eisai Co Ltd (4523) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 8
List of Figures 10
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Eisai Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14
Eisai Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deal Details 24
Asset Purchase 24
Eisai to Acquire Rights of Kolbet from Toyoma Chemical and Taisho Pharma 24
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 25
Partnerships 26
Distributed Bio Enters into Collaboration with H3 Biomedicine 26
Eisai and MSD Enter into Co-Marketing Agreement 27
KAN Research Institute Enters into Development Agreement with Six Research Organizations 28
Eisai Enters into Research Agreement with Broad Institute, Colorado State University and University of Chicago 30
Eisai Enters into Development Agreement with Sloan Pharma 31
Eisai Enters into Agreement with Nichi-Iko Pharma 32
Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck 33
Eisai and Boston University School of Medicine Enter into Research Agreement 34
Morphotek Enters into Research Agreement with Rockefeller University 35
Eisai Enters into Co-Promotion Agreement with Biogen 36
Sato Pharma, Eisai and Seren Pharma Enter into Agreement 37
EA Pharma and Mochida Pharma Enter into Joint Development Agreement 38
Ono Pharma Enters into Agreement with Eisai 39
Eisai Enters into Agreement with Merck 40
Morphotek Enters into Agreement with Johns Hopkins University School of Medicine 41
Eisai Enters into Agreement with Merck for Eribulin 42
Eisai Enters into Research Agreement with Broad Institute 43
Ewopharma and Eisai Enter into Co-Marketing Agreement 44
Oncology Venture and Eisai Enter into Agreement 45
Eisai Enters into Marketing and Distribution Agreement with Orion 46
Eisai Enters into Agreement with Keio University 47
Eisai Enters into Research Agreement with Oklahoma Medical Research Foundation 48
Morphotek Enters into Research Agreement with Fox Chase Cancer Center 49
Cancer Genetics Partners with H3 Biomedicine 50
Novartis Pharma Enters into Agreement with Eisai 51
EA Pharma Enters into Co-Promotion Agreement with AbbVie 52
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 53
Eisai Forms Joint Venture with Ajinomoto 55
Morphotek Enters into Agreement with Areva Med 56
Ajinomoto Pharma and Mochida Pharma Enter into Co-Development Agreement 57
Eisai Enters into Agreement with PIQUR Therapeutics 58
Eisai Extends Research Agreement with Charles River Labs 59
Eisai Enters into Agreement with Esteve 60
Morphotek Enters into Agreement with Mayo Clinic 61
Morphotek Enters into Research Agreement with University of Wisconsin Madison 62
Morphotek Enters into R&D Agreement with Targeted Alpha Therapy 63
Eisai Enters into Research Agreement with Medicines for Malaria Venture 64
Eisai Enters into Research Agreement with Liverpool School of Tropical Medicine and University of Liverpool 65
Eisai Enters into Research Agreement with Paoli Calmettes Institute 66
Eisai Enters into Agreement with Purdue Pharma 67
JCR Pharma Enters into Agreement with Eisai 68
Eisai Enters into Agreement with Nihon Medi-Physics 69
Kissei Pharma Enters into Co-Development Agreement with Ajinomoto Pharma 70
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 71
AbbVie Deutschland Enters into Partnership Agreement with Eisai 72
Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 73
Eisai Enters into Research Agreement with St. Jude Children’s Research Hospital and Medicines For Malaria Venture to Develop SJ733 74
Eisai Enters into Research Agreement with Broad Institute 75
Eisai Enters into Agreement with Kyorin 76
Stealth Biologics Enters into Co-Development Agreement with Morphotek 77
Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 78
Eisai and University of Tsukuba Enter into Co-Development Agreement 79
Eisai Enters Co-Development Agreement With Liverpool School Of Tropical Medicine And University of Liverpool 80
Eisai Expands Co-Development Agreement with Biogen 81
Eisai Enters into Co-Marketing Agreement with Esteve for Zonegran 83
Eisai Enters Into Co-Marketing Agreement With NewBridge Pharma For Halaven (Eribulin) 84
Eisai Enters Into Co-Development Agreement With Broad Institute For Neglected Tropical Diseases And Tuberculosis 85
Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 86
H3 Biomedicine Extends Agreement with Selvita 88
H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 89
H3 Biomedicine Enters Into Agreement With Sage Bionetworks For Cancer-Genomics Research 90
Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs 91
RaQualia Pharma Enters into Research Agreement with Ajinomoto Pharma 92
Eisai Enters Into R&D Agreement With Oswaldo Cruz Foundation For Malaria And Neglected Tropical Diseases 93
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 94
Eisai Enters Into Agreement With Sabin Vaccine Institute To Develop Vaccines For Neglected Tropical Diseases 95
Verastem Enters Into Research Agreement With Eisai For Small Molecule Wnt Inhibitors 96
Galenea Enters Into Agreement With Eisai To Develop Synaptic Modulators for Neurodegenerative Diseases 97
MicroBiopharm Japan Enters Into Co-Development Agreement With Eisai 98
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 99
Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 100
Proteros Biostructures Enters Into Drug Discovery Agreement With Eisai 101
Eisai Europe Enters Into Distribution Agreement With PharmaSwiss For Halaven 102
NanoCarrier Enters Into Co-Development Agreement With Eisai 103
Licensing Agreements 104
Eurofarma Labs Enters into Licensing Agreement with Eisai 104
BioArctic Receives Rights from Eisai 105
CY Biotech Enters into Licensing Agreement with Eisai 106
Tasly Pharma Enters into Licensing Agreement with EA Pharma 107
Morphotek Enters into Licensing Agreement with Bliss Biopharma 108
EA Pharma to Enter into Licensing Agreement with Cosmo Technologies 109
Adlai Nortye Biopharma Enters into Licensing Agreement with Eisai 110
JW Pharma Enters into Licensing Agreement with EA Pharma 111
Grupo Biotoscana Enters into Licensing Agreement with Eisai 112
Oncology Venture Enters into Licensing Agreement with Eisai 113
Eisai Enters into Licensing Agreement with Meiji Seika Pharma 114
EA Pharma Enters into Licensing Agreement with Calypso Biotech 115
Morphotek Enters into Licensing Agreement with Eurofarma Laboratorios 116
Dr. Reddy’s Labs Enters into Licensing Agreement with Eisai for E7777 117
HUYA Bioscience International Enters into Licensing Agreement with Eisai 118
Eisai Enters into License Agreement with Amplyx Pharma 119
Roivant Sciences Enters into Licensing Agreement with Eisai 120
Blaze Bioscience Enters into Licensing Agreement with Morphotek 121
LTT Bio-Pharma Enters into License Agreement with Ajinomoto Pharma 122
Lantern Pharma Enters into Licensing Agreement with Eisai 123
Boston Strategics Enters into Licensing Agreement with Eisai for E6201 124
NanoCarrier Enters into Licensing Agreement with Eisai 125
Ajinomoto Pharma Amends Licensing Agreement with Albireo for Elobixibat 126
Otsuka Pharma Enters Into Licensing Agreement With Eisai 127
Accellta Enters into Licensing Agreement with Ajinomoto 128
Eisai To Enter Into Licensing Agreement With Nobelpharma For Antineoplastic Agent Gliadel 7.7Mg Implant 129
Eisai Enters Into Licensing Agreement With Generic Drug Manufacturer For Donepezil HCl 23mg 130
Ildong Enters Into Licensing Agreement With Ajinomoto Pharma For Cilnidipine/Valsartan Drug 131
Santen Pharma And Eisai Enter Into Option Agreement For Ophthalmic Drugs 132
Eisai Enters Into Licensing Agreement With Minophagen Pharma For Bexaroten 133
Institute for OneWorld Health Enters Into Licensing Agreement With Eisai For Pro-Drug Technology Patent 134
Compendia Bioscience Enters Into Licensing Agreement With H3 Biomedicine 135
Asset Transactions 136
Riemser Pharma Acquires European Rights to Prialt from Eisai 136
Concordia Pharmaceuticals Acquires Zonegran from Eisai for USD91.5 Million 137
Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 139
Eisai Taiwan Sells Tainan Production Plant To Bora 140
Valeant Pharma Acquires US Rights To Targretin From Eisai 141
Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 142
Acquisition 144
Dova Pharma Acquires AkaRx from Eisai 144
Eisai Acquires Liaoning TianYi Biological Pharma for USD78 Million 146
Alfresa to Acquire Sannova from Eisai 147
Sekisui Chemical to Acquire Eidia from Eisai for USD182 Million 148
Robert Bosch Completes Acquisiton Of Eisai Machinery 149
Eisai Co Ltd – Key Competitors 151
Eisai Co Ltd – Key Employees 152
Eisai Co Ltd – Locations And Subsidiaries 155
Head Office 155
Other Locations & Subsidiaries 155
Joint Venture 157
Recent Developments 159
Strategy And Business Planning 159
Nov 08, 2018: Eisai commences full-scale operation of new suzhou plant in China 159
Jun 13, 2018: Eisai To Establish New Research Facility “Eisai Center For Genetics Guided Dementia Discovery” In Cambridge, Massachusetts In The United States 160
Jan 11, 2018: Eisai Completes Construction Of Oral Solid Dose Production Facility At New Suzhou Plant In China 161
Corporate Communications 162
Oct 10, 2018: Eisai to support earthquake relief efforts in sulawesi, indonesia 162
Jul 18, 2018: Eisai supports relief efforts for flooding in western Japan 163
Jun 11, 2018: Eisai Names Lihua Yu As President & Chief Data Sciences Officer Of H3 Biomedicine 164
Sep 25, 2017: Eisai to Contribute to Central Mexican Earthquake Relief Efforts 165
Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia 166
Government and Public Interest 167
Oct 31, 2017: GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma 167
Jun 28, 2017: Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment 170
Jan 18, 2017: Eisai To Participate In Access Accelerated, Global Partnership To Address Rise Of Non-Communicable Diseases 171
Product News 172
12/07/2017: Eisai and Purdue Pharma L.P. Presented Lemborexant Data from Research Studies at ACNP Annual Meeting 172
10/31/2017: Eisai To Present Latest Data On lemborexant At 10th Clinical Trials On Alzheimer’s Disease 173
10/24/2018: Eisai to present discovery of a structurally novel class of STING agonist E7766 at SITC’s 33rd Annual Meeting 174
Oct 19, 2018: Discovery of candidate compound as potential treatment for parkinson’s disease using ips cellsopening the way to establishing new techniques for developing treatments for neurological diseases 175
Oct 10, 2017: Small And Easy To Take, Just One Tablet Per Dose Eisai To Launch “Onji-No-Megumi” For Improving Forgetfulness In Middle Age And Beyond 177
09/11/2017: Eisai Presents Results of Phase Ib/II Clinical Study of Lenvima in Combination With Pembrolizumab for Renal Cell Carcinoma in Oral Session at ESMO 2017 Congress 178
07/17/2017: Eisai Presents Poster on BAN2401 at the 2017 Alzheimer’s Association International Conference 180
06/15/2017: Inhibitor Drug Improves Overall Survival in Older Radioiodine Resistant Thyroid Cancer Patients 181
06/05/2017: Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab for the Treatment of Endometrial Carcinoma at 53rd ASCO Annual Meeting 182
06/02/2017: Further Study of Combination of Eisais Lenvatinib and Merck’s Pembrolizumab in Previously Treated Patients with Metastatic Endometrial Cancer Supported by Interim Analysis of Ongoing Phase 1b/2 Trial 184
04/05/2017: Eisai Presents Data Of Mechanisms Of Action Relating To Tumor Immune Response Regarding Combination Of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody At AACR 108th Annual Meeting 186
03/28/2017: Eisai to Present Data on Lenvima at 2017 AACR Annual Meeting 187
03/28/2017: German Federal Joint Committee (G-BA) Confirms Additional Benefit of Kisplyx (lenvatinib) in Treatment of Advanced Renal Cell Carcinoma 189
03/23/2018: Anticancer Agent LENVIMA (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC 190
03/12/2018: Grupo Biotoscana Announces New Initiatives for LENVIMA 191
01/09/2018: Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA (lenvatinib mesylate) and KEYTRUDA (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell Carcinoma 192
01/04/2017: German Institute for Quality and Efficiency in Health Care Confirms Additional Benefit for Kisplyx (lenvatinib) in Combination with everolimus for the Treatment of Advanced Renal Cell Carcinoma 194
01/03/2018: Clinigen Seeks Marketing Authorisation and Launch Lenvima in Africa 196
Product Approvals 197
Feb 16, 2018: UK NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer 197
Jan 26, 2018: NICE Issues Technology Appraisal Guidance on Lenvatinib with Everolimus for Previously Treated Advanced RCC 198
Dec 27, 2017: Anticancer Agent Lenvatinib Designated For Priority Review And Approval By China Food And Drug Administration For Hepatocellular Carcinoma 200
Dec 11, 2017: Eisai salutes positive NICE Recommendation for Kisplyx (lenvatinib) for the treatment of advanced renal cell carcinoma 201
Dec 06, 2017: Eisai Submits Application For Expanded Indication Covering Hepatocellular Carcinoma For Anticancer Agent Lenvima In Taiwan 202
Oct 31, 2017: New Drug Application Of Anticancer Agent Lenvatinib For Hepatocellular Carcinoma Accepted In China 203
Sep 27, 2017: Application for Additional Indication of Lenvima for Hepatocellular Carcinoma Accepted for Review by U.S. FDA 205
Sep 26, 2017: FDA Accepts Supplemental New Drug Application for Eisais Lenvatinib for the Treatment of Liver Cancer 207
Jul 25, 2017: Eisai submits simultaneous applications in the united states and europe for lenvatinib in hepatocellular carcinoma 209
Jun 23, 2017: Eisai Submits Application For Additional Indication Of Anticancer Agent Lenvima For Hepatocellular Carcinoma In Japan 210
Clinical Trials 212
Sep 14, 2018: £1.5M to develop candidate drug to treat onchocerciasis and lymphatic filariasis 212
May 22, 2018: Eisai and Purdue Pharma Announce Key Phase 1 Clinical Studies of Lemborexant to be Presented at the 32nd Annual SLEEP Meeting 213
Mar 07, 2018: Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant 215
Feb 15, 2018: Positive Phase 3 Trial Results of Investigational Anticancer Agent Lenvatinib in Unresectable Hepatocellular Carcinoma (HCC) Published in The Lancet 217
Feb 10, 2018: Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in the Lancet 219
Jan 22, 2018: Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib) In Hepatocellular Carcinoma Based on Independent Imaging Review at ASCO-GI 220
Dec 21, 2017: BioArctic announces that the Phase 2b study of BAN2401 in early Alzheimer´s Disease continues toward 18 month endpoint 222
Sep 29, 2017: Eisai Presents Results of Phase III Trial of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma in Oral Session at 20th CSCO Annual Meeting 224
Sep 19, 2017: Eisai Presents Results Of Phase III Clinical Study Of Lenvima (Lenvatinib) In Unresectable Hepatocellular Carcinoma At 11th ILCA Annual Conference 226
Sep 11, 2017: Eisai Presents New Quality of Life Findings in Hepatocellular Carcinoma Patients from Lenvatinib Versus Sorafenib Study in Oral Session at ESMO Congress 228
Sep 01, 2017: Eisai to Present 3 Abstracts on Lenvima at ESMO 2017 Congress 230
Sep 01, 2017: Eisai to Present Abstract on E7046 at ESMO 2017 Congress 232
Sep 01, 2017: Eisai to Present Abstract on its Oncology Product Candidate E7046 at the ESMO 2017 Congress 233
Sep 01, 2017: Eisai To Present Abstracts On Oncology Products And Pipeline At ESMO 2017 Congress 234
Aug 28, 2017: Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According to Results of Subanalysis of Phase 3 SELECT Trial 236
Jul 17, 2017: Eisai Presents 3 Posters on E2027 at the 2017 Alzheimer’s Association International Conference 238
Jun 05, 2017: Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd Asco Annual Meeting 239
Jun 04, 2017: Lenvatinib Demonstrates Positive Results vs Sorafenib Across All Endpoints in First-Line Phase 3 Non-inferiority Trial of Unresectable Hepatocellular Carcinoma (uHCC) 241
May 18, 2017: Eisai to Present Abstracts on Lenvatinib At 53rd ASCO Annual Meeting 243
Jan 25, 2017: Phase III Trial Of Anticancer Agent Lenvima As First-Line Treatment For Unresectable Hepatocellular Carcinoma Meets Primary Endpoint 244
Appendix 245
Methodology 245
About GlobalData 245
Contact Us 245
Disclaimer 245

List of Tables
Eisai Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Eisai Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Eisai Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 14
Eisai Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17
Eisai to Acquire Rights of Kolbet from Toyoma Chemical and Taisho Pharma 24
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 25
Distributed Bio Enters into Collaboration with H3 Biomedicine 26
Eisai and MSD Enter into Co-Marketing Agreement 27
KAN Research Institute Enters into Development Agreement with Six Research Organizations 28
Eisai Enters into Research Agreement with Broad Institute, Colorado State University and University of Chicago 30
Eisai Enters into Development Agreement with Sloan Pharma 31
Eisai Enters into Agreement with Nichi-Iko Pharma 32
Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck 33
Eisai and Boston University School of Medicine Enter into Research Agreement 34
Morphotek Enters into Research Agreement with Rockefeller University 35
Eisai Enters into Co-Promotion Agreement with Biogen 36
Sato Pharma, Eisai and Seren Pharma Enter into Agreement 37
EA Pharma and Mochida Pharma Enter into Joint Development Agreement 38
Ono Pharma Enters into Agreement with Eisai 39
Eisai Enters into Agreement with Merck 40
Morphotek Enters into Agreement with Johns Hopkins University School of Medicine 41
Eisai Enters into Agreement with Merck for Eribulin 42
Eisai Enters into Research Agreement with Broad Institute 43
Ewopharma and Eisai Enter into Co-Marketing Agreement 44
Oncology Venture and Eisai Enter into Agreement 45
Eisai Enters into Marketing and Distribution Agreement with Orion 46
Eisai Enters into Agreement with Keio University 47
Eisai Enters into Research Agreement with Oklahoma Medical Research Foundation 48
Morphotek Enters into Research Agreement with Fox Chase Cancer Center 49
Cancer Genetics Partners with H3 Biomedicine 50
Novartis Pharma Enters into Agreement with Eisai 51
EA Pharma Enters into Co-Promotion Agreement with AbbVie 52
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 53
Eisai Forms Joint Venture with Ajinomoto 55
Morphotek Enters into Agreement with Areva Med 56
Ajinomoto Pharma and Mochida Pharma Enter into Co-Development Agreement 57
Eisai Enters into Agreement with PIQUR Therapeutics 58
Eisai Extends Research Agreement with Charles River Labs 59
Eisai Enters into Agreement with Esteve 60
Morphotek Enters into Agreement with Mayo Clinic 61
Morphotek Enters into Research Agreement with University of Wisconsin Madison 62
Morphotek Enters into R&D Agreement with Targeted Alpha Therapy 63
Eisai Enters into Research Agreement with Medicines for Malaria Venture 64
Eisai Enters into Research Agreement with Liverpool School of Tropical Medicine and University of Liverpool 65
Eisai Enters into Research Agreement with Paoli Calmettes Institute 66
Eisai Enters into Agreement with Purdue Pharma 67
JCR Pharma Enters into Agreement with Eisai 68
Eisai Enters into Agreement with Nihon Medi-Physics 69
Kissei Pharma Enters into Co-Development Agreement with Ajinomoto Pharma 70
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 71
AbbVie Deutschland Enters into Partnership Agreement with Eisai 72
Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 73
Eisai Enters into Research Agreement with St. Jude Children's Research Hospital and Medicines For Malaria Venture to Develop SJ733 74
Eisai Enters into Research Agreement with Broad Institute 75
Eisai Enters into Agreement with Kyorin 76
Stealth Biologics Enters into Co-Development Agreement with Morphotek 77
Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 78
Eisai and University of Tsukuba Enter into Co-Development Agreement 79
Eisai Enters Co-Development Agreement With Liverpool School Of Tropical Medicine And University of Liverpool 80
Eisai Expands Co-Development Agreement with Biogen 81
Eisai Enters into Co-Marketing Agreement with Esteve for Zonegran 83
Eisai Enters Into Co-Marketing Agreement With NewBridge Pharma For Halaven (Eribulin) 84
Eisai Enters Into Co-Development Agreement With Broad Institute For Neglected Tropical Diseases And Tuberculosis 85
Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 86
H3 Biomedicine Extends Agreement with Selvita 88
H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 89
H3 Biomedicine Enters Into Agreement With Sage Bionetworks For Cancer-Genomics Research 90
Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs 91
RaQualia Pharma Enters into Research Agreement with Ajinomoto Pharma 92
Eisai Enters Into R&D Agreement With Oswaldo Cruz Foundation For Malaria And Neglected Tropical Diseases 93
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 94
Eisai Enters Into Agreement With Sabin Vaccine Institute To Develop Vaccines For Neglected Tropical Diseases 95
Verastem Enters Into Research Agreement With Eisai For Small Molecule Wnt Inhibitors 96
Galenea Enters Into Agreement With Eisai To Develop Synaptic Modulators for Neurodegenerative Diseases 97
MicroBiopharm Japan Enters Into Co-Development Agreement With Eisai 98
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 99
Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 100
Proteros Biostructures Enters Into Drug Discovery Agreement With Eisai 101
Eisai Europe Enters Into Distribution Agreement With PharmaSwiss For Halaven 102
NanoCarrier Enters Into Co-Development Agreement With Eisai 103
Eurofarma Labs Enters into Licensing Agreement with Eisai 104
BioArctic Receives Rights from Eisai 105
CY Biotech Enters into Licensing Agreement with Eisai 106
Tasly Pharma Enters into Licensing Agreement with EA Pharma 107
Morphotek Enters into Licensing Agreement with Bliss Biopharma 108
EA Pharma to Enter into Licensing Agreement with Cosmo Technologies 109
Adlai Nortye Biopharma Enters into Licensing Agreement with Eisai 110
JW Pharma Enters into Licensing Agreement with EA Pharma 111
Grupo Biotoscana Enters into Licensing Agreement with Eisai 112
Oncology Venture Enters into Licensing Agreement with Eisai 113
Eisai Enters into Licensing Agreement with Meiji Seika Pharma 114
EA Pharma Enters into Licensing Agreement with Calypso Biotech 115
Morphotek Enters into Licensing Agreement with Eurofarma Laboratorios 116
Dr. Reddy's Labs Enters into Licensing Agreement with Eisai for E7777 117
HUYA Bioscience International Enters into Licensing Agreement with Eisai 118
Eisai Enters into License Agreement with Amplyx Pharma 119
Roivant Sciences Enters into Licensing Agreement with Eisai 120
Blaze Bioscience Enters into Licensing Agreement with Morphotek 121
LTT Bio-Pharma Enters into License Agreement with Ajinomoto Pharma 122
Lantern Pharma Enters into Licensing Agreement with Eisai 123
Boston Strategics Enters into Licensing Agreement with Eisai for E6201 124
NanoCarrier Enters into Licensing Agreement with Eisai 125
Ajinomoto Pharma Amends Licensing Agreement with Albireo for Elobixibat 126
Otsuka Pharma Enters Into Licensing Agreement With Eisai 127
Accellta Enters into Licensing Agreement with Ajinomoto 128
Eisai To Enter Into Licensing Agreement With Nobelpharma For Antineoplastic Agent Gliadel 7.7Mg Implant 129
Eisai Enters Into Licensing Agreement With Generic Drug Manufacturer For Donepezil HCl 23mg 130
Ildong Enters Into Licensing Agreement With Ajinomoto Pharma For Cilnidipine/Valsartan Drug 131
Santen Pharma And Eisai Enter Into Option Agreement For Ophthalmic Drugs 132
Eisai Enters Into Licensing Agreement With Minophagen Pharma For Bexaroten 133
Institute for OneWorld Health Enters Into Licensing Agreement With Eisai For Pro-Drug Technology Patent 134
Compendia Bioscience Enters Into Licensing Agreement With H3 Biomedicine 135
Riemser Pharma Acquires European Rights to Prialt from Eisai 136
Concordia Pharmaceuticals Acquires Zonegran from Eisai for USD91.5 Million 137
Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 139
Eisai Taiwan Sells Tainan Production Plant To Bora 140
Valeant Pharma Acquires US Rights To Targretin From Eisai 141
Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 142
Dova Pharma Acquires AkaRx from Eisai 144
Eisai Acquires Liaoning TianYi Biological Pharma for USD78 Million 146
Alfresa to Acquire Sannova from Eisai 147
Sekisui Chemical to Acquire Eidia from Eisai for USD182 Million 148
Robert Bosch Completes Acquisiton Of Eisai Machinery 149
Eisai Co Ltd, Key Competitors 151
Eisai Co Ltd, Key Employees 152
Eisai Co Ltd, Subsidiaries 155
Eisai Co Ltd, Joint Venture 157

List of Figures
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14
Eisai Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16

★海外企業調査レポート[Eisai Co Ltd (4523)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Symbolic Displays Inc：企業の戦略・SWOT・財務情報
    Symbolic Displays Inc - Strategy, SWOT and Corporate Finance Report Summary Symbolic Displays Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Central Garden & Pet Company：企業の戦略・SWOT・財務情報
    Central Garden & Pet Company - Strategy, SWOT and Corporate Finance Report Summary Central Garden & Pet Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • TETRA Technologies Inc (TTI)：企業の財務・戦略的SWOT分析
    Summary TETRA Technologies Inc (TETRA) is an oil and gas company that offers completion fluids and associated products and services. The company’s services comprise compression services, fluid, filtration and tools services, offshore services, production testing, rig cooling services, technology cen …
  • Endesa SA：発電所・企業SWOT分析
    Endesa SA - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executiv …
  • FBD Holdings Plc (EG7)：企業の財務・戦略的SWOT分析
    FBD Holdings Plc (EG7) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Cognizant Technology Solutions Corporation：企業のM&A・事業提携・投資動向
    Cognizant Technology Solutions Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cognizant Technology Solutions Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detai …
  • Toyo Tire & Rubber Co Ltd (5105)：企業の財務・戦略的SWOT分析
    Toyo Tire & Rubber Co Ltd (5105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Hasbro Inc (HAS)：企業の財務・戦略的SWOT分析
    Hasbro Inc (HAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Rath AG：企業の戦略・SWOT・財務情報
    Rath AG - Strategy, SWOT and Corporate Finance Report Summary Rath AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Integer Holdings Corp (ITGR)-医療機器分野：企業M&A・提携分析
    Summary Integer Holdings Corp (Integrated Holdings), formerly Greatbatch Inc is a medical device outsource manufacturer that designs and develops medical devices and power solutions for the medical and non-medical markets. The company offers products such as arthroscopic devices and components, lapa …
  • Taiyo Nippon Sanso Corp (4091)：企業の財務・戦略的SWOT分析
    Taiyo Nippon Sanso Corp (4091) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Sanofi (SAN)：企業の財務・戦略的SWOT分析
    Sanofi (SAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Warpaint London plc (W7L)：企業の財務・戦略的SWOT分析
    Warpaint London plc (W7L) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Sekisui House Ltd (1928)：企業の財務・戦略的SWOT分析
    Sekisui House Ltd (1928) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Reichhold LLC 2：企業の戦略的SWOT分析
    Reichhold LLC 2 - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Advanced Accelerator Applications SA：製薬・医療：M&Aディール及び事業提携情報
    Summary Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company’s lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnas …
  • A123 Systems LLC：企業の戦略的SWOT分析
    A123 Systems LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • The Walt Disney Company (DIS)：企業の財務・戦略的SWOT分析
    The Walt Disney Company (DIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Romaero SA Bucuresti：企業の戦略・SWOT・財務情報
    Romaero SA Bucuresti - Strategy, SWOT and Corporate Finance Report Summary Romaero SA Bucuresti - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Trusted Media Brands, Inc.：企業の戦略的SWOT分析
    Trusted Media Brands, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆